Bristol's $1 billion Bavarian deal may signal cancer vaccine revival

March 4, 2015 3:45 PM

16 0

LONDON (Reuters) - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic.

The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's therapeutic prostate cancer vaccine Prostvac and signals that such shots may have a bright future when combined with so-called checkpoint inhibitor drugs.

Also read: The $24 Billion Job: An Energy CEO’s Quest to Reshape Gas Exports

Read more

To category page